Compare FCBC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | SVRA |
|---|---|---|
| Founded | 1874 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.3M | 1.1B |
| IPO Year | 1996 | 2009 |
| Metric | FCBC | SVRA |
|---|---|---|
| Price | $47.15 | $5.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 73.2K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $2.55 | $430.87 |
| P/E Ratio | $25.69 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.21 | $3.34 |
| 52 Week High | $50.17 | $7.01 |
| Indicator | FCBC | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 38.18 |
| Support Level | $42.49 | $4.77 |
| Resistance Level | $49.84 | $5.48 |
| Average True Range (ATR) | 1.01 | 0.21 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 44.62 | 12.33 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).